213 related articles for article (PubMed ID: 37476530)
1. Implication of Serious Infections in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the First Cycle of Rituximab: A Pilot Study in a Single Korean Center.
Do H; Pyo JY; Sup ; Sup ; Song JJ; Sup ; Sup ; Park YB; Sup ; Sup ; Lee SW; Sup ; Sup
J Rheum Dis; 2023 Jan; 30(1):45-52. PubMed ID: 37476530
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
[TBL] [Abstract][Full Text] [Related]
5. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
7. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
Segelmark L; Flores-Suárez L; Mohammad A
Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.
Krishna R; De Giacomi F; Kumar N; Kalina P; Specks U; Baqir M
J Clin Rheumatol; 2021 Mar; 27(2):64-72. PubMed ID: 31567753
[TBL] [Abstract][Full Text] [Related]
9. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Springer JM; Funk RS
J Rheumatol; 2021 Nov; 48(11):1718-1724. PubMed ID: 34334366
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.
Habibi MA; Alesaeidi S; Zahedi M; Hakimi Rahmani S; Piri SM; Tavakolpour S
Biology (Basel); 2022 Dec; 11(12):. PubMed ID: 36552276
[No Abstract] [Full Text] [Related]
12. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592
[TBL] [Abstract][Full Text] [Related]
13. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
[TBL] [Abstract][Full Text] [Related]
15. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of Korean elderly patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Yoo BW; Song JJ; Park YB; Lee SW
Korean J Intern Med; 2021 May; 36(3):731-741. PubMed ID: 32811130
[TBL] [Abstract][Full Text] [Related]
17. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study.
Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T
Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536
[TBL] [Abstract][Full Text] [Related]
18. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
19. Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Néel A; Bucchia M; Néel M; Tilly G; Caristan A; Yap M; Rimbert M; Bruneau S; Cadoux M; Agard C; Hourmant M; Godmer P; Brouard S; Bressollette C; Hamidou M; Josien R; Fakhouri F; Degauque N
Arthritis Rheumatol; 2019 Apr; 71(4):641-650. PubMed ID: 30375745
[TBL] [Abstract][Full Text] [Related]
20. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
